{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:58:56Z","timestamp":1790758736630,"version":"4.1.0"},"reference-count":50,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"unspecified","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,8,24]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gastric cancer (GC) derives limited benefit from immunotherapy, with clinical responses observed in only a minority of patients. Increasing evidence suggests that heterogeneity within the tumor immune microenvironment (TME) is a critical determinant of immunotherapeutic efficacy, highlighting the need for precise immune stratification and the identification of molecular biomarkers that shape the TME.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We integrated single-cell transcriptomic data from our cohort and public datasets to characterize immune microenvironment heterogeneity in GC. Functional experiments were performed using in vitro assays and in vivo mouse models to investigate the molecular mechanisms regulating immune exhaustion. Clinical relevance was evaluated using tumor specimens from patients with GC receiving anti-programmed cell death protein 1 (PD-1) therapy. Survival analyses and biomarker evaluation were conducted to assess the prognostic and predictive value of candidate markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified two distinct GC immune microenvironment subtypes: the immunosuppressive (GC1) and the immune-activated (GC2). PRKX was identified as a key regulator associated with immune heterogeneity and exhaustion. Clinically, a high density of PanCK\n                      <jats:sup>+<\/jats:sup>\n                      PRKX\n                      <jats:sup>+<\/jats:sup>\n                      PD-L1\n                      <jats:sup>+<\/jats:sup>\n                      tumor cells was significantly associated with poor prognosis and served as a robust biomarker predicting 5-year survival in patients treated with anti-PD-1 therapy. Mechanistically, PRKX phosphorylates programmed death-ligand 1 (PD-L1) at T285, promoting YWHAE recruitment and preventing UBE2M-mediated ubiquitination and degradation, thereby stabilizing PD-L1 protein. Through this phosphorylation-dependent regulation of PD-L1 stability, PRKX suppresses CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell cytotoxicity, promotes immune exhaustion, and limits the efficacy of anti-PD-1 therapy in vivo. Therapeutically, lipid nanoparticle-mediated delivery of PRKX-targeting siRNA effectively suppressed PRKX expression and synergized with anti-PD-1 therapy to enhance antitumor efficacy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PRKX drives immune exhaustion in the GC1 subtype by stabilizing PD-L1 through phosphorylation-dependent inhibition of ubiquitination, thereby promoting immune evasion. Targeting PRKX represents a potential strategy to overcome resistance to anti-PD-1 therapy, and PRKX expression may serve as a prognostic biomarker to guide immunotherapy in GC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-015452","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:40:52Z","timestamp":1788957652000},"page":"e015452","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["PRKX-mediated stabilization of PD-L1 characterizes an immunosuppressive gastric cancer subtype"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04065282","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Qiyue","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinqi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"},{"name":"Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongshuo","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejun","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzhi","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjie","family":"Li","sequence":"additional","affiliation":[{"name":"Sichuan Kelun-Biotech Biopharmaceutical Co, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Shao","sequence":"additional","affiliation":[{"name":"Clinical Medicine of Traditional Chinese and Western Medicine, Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ruan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4394-6176","authenticated-orcid":false,"given":"Haiping","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"2026093001151218000_14.9.e015452.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00052-2"},{"key":"2026093001151218000_14.9.e015452.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"2026093001151218000_14.9.e015452.3","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.7150\/ijbs.56735","article-title":"Progress of Gastric Cancer Surgery in the era of Precision Medicine","volume":"17","author":"Wang","year":"2021","journal-title":"Int J Biol Sci"},{"key":"2026093001151218000_14.9.e015452.4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i8.2403"},{"key":"2026093001151218000_14.9.e015452.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.12.004"},{"key":"2026093001151218000_14.9.e015452.6","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01451-3","article-title":"Gastric cancer treatment: recent progress and future perspectives","volume":"16","author":"Guan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2026093001151218000_14.9.e015452.7","doi-asserted-by":"crossref","first-page":"104197","DOI":"10.1016\/j.critrevonc.2023.104197","article-title":"Immunotherapy and targeted therapy as first-line treatment for advanced gastric cancer","volume":"198","author":"Wang","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026093001151218000_14.9.e015452.8","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0008"},{"key":"2026093001151218000_14.9.e015452.9","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026093001151218000_14.9.e015452.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918"},{"key":"2026093001151218000_14.9.e015452.11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10120-021-01227-z","article-title":"Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial","volume":"25","author":"Fuchs","year":"2022","journal-title":"Gastric Cancer"},{"key":"2026093001151218000_14.9.e015452.12","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-024-03726-1","article-title":"The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis","volume":"73","author":"Li","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"2026093001151218000_14.9.e015452.13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.trecan.2024.03.008","article-title":"Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development","volume":"10","author":"Yasuda","year":"2024","journal-title":"Trends Cancer"},{"key":"2026093001151218000_14.9.e015452.14","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-024-03938-5","article-title":"The profiles of immunosuppressive microenvironment in the Lauren intestinal-type gastric adenocarcinoma","volume":"74","author":"Wang","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"2026093001151218000_14.9.e015452.15","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-025-04173-2","article-title":"The single-cell atlas of colorectal cancer reveals cellular heterogeneity and key molecular features of the tumor immune microenvironment","volume":"74","author":"Li","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"2026093001151218000_14.9.e015452.16","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00011-024-01905-5","article-title":"Comprehensive analysis of single cell and bulk RNA sequencing reveals the heterogeneity of melanoma tumor microenvironment and predicts the response of immunotherapy","volume":"73","author":"Zhang","year":"2024","journal-title":"Inflamm Res"},{"key":"2026093001151218000_14.9.e015452.17","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-025-00808-w","article-title":"Single-cell RNA sequencing reveals different cellular states in malignant cells and the tumor microenvironment in primary and metastatic ER-positive breast cancer","volume":"11","author":"Ozmen","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"2026093001151218000_14.9.e015452.18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1230135","article-title":"Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy","volume":"14","author":"Feng","year":"2023","journal-title":"Front Immunol"},{"key":"2026093001151218000_14.9.e015452.19","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-01027-5","article-title":"Regulation of PD-L1 expression in the tumor microenvironment","volume":"14","author":"Yi","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2026093001151218000_14.9.e015452.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-020-0562-4"},{"key":"2026093001151218000_14.9.e015452.21","doi-asserted-by":"crossref","DOI":"10.1186\/s13020-025-01146-6","article-title":"Emodin promotes GSK-3\u03b2-mediated PD-L1 proteasomal degradation and enhances anti-tumor immunity in hepatocellular carcinoma","volume":"20","author":"Yang","year":"2025","journal-title":"Chin Med"},{"key":"2026093001151218000_14.9.e015452.22","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202410586","article-title":"Platinum-Metformin Conjugates Acting as Promising PD-L1 Inhibitors through the AMP-Activated Protein Kinase Mediated Lysosomal Degradation Pathway","volume":"63","author":"Liu","year":"2024","journal-title":"Angew Chem Int Ed Engl"},{"key":"2026093001151218000_14.9.e015452.23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126022"},{"key":"2026093001151218000_14.9.e015452.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2022.101097"},{"key":"2026093001151218000_14.9.e015452.25","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-34346-x","article-title":"Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation","volume":"13","author":"Shi","year":"2022","journal-title":"Nat Commun"},{"key":"2026093001151218000_14.9.e015452.26","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.730","article-title":"Revealing the transcriptional heterogeneity of organ-specific metastasis in human gastric cancer using single-cell RNA Sequencing","volume":"12","author":"Jiang","year":"2022","journal-title":"Clin Transl Med"},{"key":"2026093001151218000_14.9.e015452.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.04.052"},{"key":"2026093001151218000_14.9.e015452.28","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-022-00251-1","article-title":"Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity","volume":"6","author":"Kim","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"2026093001151218000_14.9.e015452.29","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02532-w","article-title":"AQP5 complements LGR5 to determine the fates of gastric cancer stem cells through regulating ULK1 ubiquitination","volume":"41","author":"Zhao","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"2026093001151218000_14.9.e015452.30","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s10120-023-01456-4","article-title":"Tumor-infiltrating monocytic myeloid-derived suppressor cells contribute to the development of an immunosuppressive tumor microenvironment in gastric cancer","volume":"27","author":"Tsutsumi","year":"2024","journal-title":"Gastric Cancer"},{"key":"2026093001151218000_14.9.e015452.31","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1038\/s41388-024-03114-0","article-title":"Single-cell profiling reveals altered immune landscape and impaired NK cell function in gastric cancer liver metastasis","volume":"43","author":"Tang","year":"2024","journal-title":"Oncogene"},{"key":"2026093001151218000_14.9.e015452.32","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jare.2024.10.012","article-title":"Single-cell transcriptomic profiling uncovers cellular complexity and microenvironment in gastric tumorigenesis associated with Helicobacter pylori","volume":"74","author":"Li","year":"2025","journal-title":"J Adv Res"},{"key":"2026093001151218000_14.9.e015452.33","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/j.devcel.2025.06.034","article-title":"Concerted changes in Epithelium and Stroma: a multi-scale, multi-omics analysis of progression from Barrett\u2019s Esophagus to adenocarcinoma","volume":"60","author":"Strasser","year":"2025","journal-title":"Dev Cell"},{"key":"2026093001151218000_14.9.e015452.34","doi-asserted-by":"crossref","unstructured":"Kim B . Western blot techniques. In: Espina V , ed. Molecular profiling. New York, NY: Springer New York, 2017: 133\u20139. Available: https:\/\/doi.org\/10.1007\/978-1-4939-6990-6_9","DOI":"10.1007\/978-1-4939-6990-6_9"},{"key":"2026093001151218000_14.9.e015452.35","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ab.2006.11.032","article-title":"A single nucleotide polymorphism genotyping method using phosphate-affinity polyacrylamide gel electrophoresis","volume":"361","author":"Kinoshita","year":"2007","journal-title":"Anal Biochem"},{"key":"2026093001151218000_14.9.e015452.36","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-024-02017-7","article-title":"Helicobacter pylori infection promotes M1 macrophage polarization and gastric inflammation by activation of NLRP3 inflammasome via TNF\/TNFR1 axis","volume":"23","author":"Fei","year":"2025","journal-title":"Cell Commun Signal"},{"key":"2026093001151218000_14.9.e015452.37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003635","article-title":"Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study","volume":"10","author":"Jiang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026093001151218000_14.9.e015452.38","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/jcb.25304","article-title":"PRKX, a Novel cAMP-Dependent Protein Kinase Member, Plays an Important Role in Development","volume":"117","author":"Huang","year":"2016","journal-title":"J Cell Biochem"},{"key":"2026093001151218000_14.9.e015452.39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.132051799"},{"key":"2026093001151218000_14.9.e015452.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2018.06.002"},{"key":"2026093001151218000_14.9.e015452.41","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-30707-8","article-title":"The Ube2m-Rbx1 neddylation-Cullin-RING-Ligase proteins are essential for the maintenance of Regulatory T cell fitness","volume":"13","author":"Wu","year":"2022","journal-title":"Nat Commun"},{"key":"2026093001151218000_14.9.e015452.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.07.054"},{"key":"2026093001151218000_14.9.e015452.43","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-020-00774-4","article-title":"Targeted Therapies in Advanced Gastric Cancer","volume":"21","author":"Patel","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"2026093001151218000_14.9.e015452.44","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/his.15207","article-title":"Gastric cancer molecular classification based on immunohistochemistry and in-situ hybridisation and mortality","volume":"85","author":"Eskuri","year":"2024","journal-title":"Histopathology"},{"key":"2026093001151218000_14.9.e015452.45","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1158\/1078-0432.CCR-24-3473","article-title":"Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer","volume":"31","author":"Walch","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026093001151218000_14.9.e015452.46","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-021-00186-z","article-title":"Identification of gastric cancer subtypes based on pathway clustering","volume":"5","author":"Li","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"2026093001151218000_14.9.e015452.47","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12632","article-title":"Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity","volume":"7","author":"Li","year":"2016","journal-title":"Nat Commun"},{"key":"2026093001151218000_14.9.e015452.48","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9111702","article-title":"Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave","volume":"9","author":"Yu","year":"2021","journal-title":"Biomedicines"},{"key":"2026093001151218000_14.9.e015452.49","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-37617-3","article-title":"Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy","volume":"14","author":"Yi","year":"2023","journal-title":"Nat Commun"},{"key":"2026093001151218000_14.9.e015452.50","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202303261","article-title":"Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy","volume":"35","author":"Zong","year":"2023","journal-title":"Adv Mater"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:15:29Z","timestamp":1790756129000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,9]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/jitc-2026-015452"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015452","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}